PDpoietin in Comparison With Eprex in Treatment of Anemic Patients on Hemodialysis

Argani, Hassan; Ossareh, Shahrzad; Tabiban, Samira; Ganji, Mohammad Reza; Nafar, Mohsen; Abdi, Ezzatollah; Alipour, Behrang
July 2009
Iranian Journal of Kidney Diseases;Jul2009, Vol. 3 Issue 3, p145
Academic Journal
Introduction. PDpoietin is a recombinant erythropoietin alfa that has been introduced by a manufacturer in Iran. We assessed the effectiveness and complications of PDpoietin in comparison with Eprex in anemic patients on hemodialysis. Materials and Methods. This clinical trial was performed in a multicenter setting. Patients with a hemoglobin level less than 12 g/dL were assigned into 2 groups in order to receive either Eprex (Janssen Cilag) or PDpoietin (Pooyesh Darou) for 3 months. Results. Forty-one and 34 patients completed the study in the PDpoietin and Eprex groups, respectively. The mean hemoglobin levels at baseline were not significantly different between the two groups of patients with PDpoietin and Eprex. In both groups, hemoglobin levels increased significantly, but there were no significant differences between the two groups at months 1, 2, and 3. At the end of the study, the mean hemoglobin levels reached 11.6 ± 1.7 g/dL and 11.8 ± 1.9 g/dL, respectively (P = .002; P = .01). The mean hemoglobin per cumulative of drug dose index (hemoglobin/[erythropoietin dose/1000 x injections per month]) was not significantly different between the two groups at different treatment stages, and it did not change significantly in each group during the course of the study. No serious complications were reported. Conclusions. Eprex and PDpoietin could equally increase the hemoglobin levels with no significant complication. Therefore, PDpoietin can be used for treatment of anemia in patients on dialysis, and the patients will have the advantages of its availability and low price.


Related Articles

  • Use of Epoetin in Chronic Renal Failure. Coyne, Daniel W. // JAMA: Journal of the American Medical Association;4/18/2007, Vol. 297 Issue 15, p1713 

    The article presents an editorial that discusses a report by Thamer and colleagues in the current issue about the dosage of the drug epoetin, used to treat anemia in dialysis patients, in U.S. dialysis facilities. The author comments on a warning issued by the U.S. Food and Drug Administration...

  • Uticaj nivoa hemoglobina i visine doze rekombinantnog humanog beta eritropoetina na preživljavanje bolesnika na hemodijalizi. Knežević, Violeta; Milošević, Aleksandra; Vodopivec, Slavenka; Božić, Dušan; Budošan, Ivana; Majić, Milena // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Sep2011, Vol. 68 Issue 9, p749 

    Background/Aim. In patients with end-stage renal disease, treatment with erythropoietin lowers cardiovascular morbidity, improves quality of life and patient survival. The aim of this study was to determine the difference in survival of hemodialysis patients treated with recombinant human beta...

  • Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Casati, Stefano; Passerini, Patrizia; Campise, Maria Rosaria; Graziani, Giorgio; Cesana, Bruno; Perisic, Michael; Ponticelli, Claudio // British Medical Journal (Clinical Research Edition);10/24/1987, Vol. 295 Issue 6605, p1017 

    Examines the benefits and risks of protracted treatment with human recombinant erythropoietin in patients having hemodialysis. Increase in hemoglobin concentrations; Occurrence of thrombosis of arteriovenous fistulas in patients; Effect of the full correction of anemia on hypertensive patients.

  • Darbepoetin Alfa: A Review of its Use in the Treatment of Anaemia in Patients with Cancer Receiving Chemotherapy. Siddiqui, M. Asif A.; Keating, Gillian M. // Drugs;2006, Vol. 66 Issue 7, p997 

    Darbepoetin alfa (Aranesp) is an analogue of recombinant human erythropoietin (rHuEPO) produced using recombinant DNA technology. The high number of sialic acid moieties in darbepoetin alfa results in a prolonged half-life and enhanced in vivo biological activity compared with rHuEPO (as...

  • Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990–1996. Cotter, Dennis J.; Thamer, Mae; Kimmel, Paul L.; Sadler, John H. // Kidney International;Dec1998, Vol. 54 Issue 6, p2129 

    Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990–1996 . Background. Chronic anemia is a major cause of morbidity among the end-stage renal disease (ESRD) population. Recombinant erythropoietin (rHuEPO) has been recognized as a major advance...

  • Global standardisation of HbA1c. Lai, Leslie C. // Malaysian Journal of Pathology;Dec2008, Vol. 30 Issue 2, p67 

    HbA1c is used for assessing glycaemic control in patients with diabetes. It is also used for treatment goals and as a target for therapeutic intervention. The Direct Control and Complications Trial in the USA showed that HbA1c can be used to predict the risk of complications. Hence, it is...

  • Laparoscopic Transperitoneal Ureterolithotomy. Ahmed El-Feel; Hazem Abouel-Fettouh; Amr M. Abdel-Hakim // Journal of Endourology;Jan2007, Vol. 21 Issue 1, p50 

    Purpose To present our experience with laparoscopic ureterolithotomy as a potential alternative to open ureterolithotomy.Patients and Methods Between October 2003 and October 2005, a total of 27 laparoscopic ureterolithotomies were performed in 25 patients. The mean age of the patients was 39.8...

  • Spectrophotometric determination of hemoglobin with p-acetylarsenazo. Q.-Z.ai; J.-M.; Chen, T. // Journal of Analytical Chemistry;May2007, Vol. 62 Issue 5, p428 

    In a Britton-Robinson buffer medium at pH 2.87, hemoglobin can form a color compound with p-acetylarsenazo in the presence of emulgent OP. The maximum absorption locates at 370 nm. The apparent molar absorptivity ɛ370 nm is 4.11 × 105 L/(mol cm). Beer’s law is obeyed over the...

  • Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Ma, Q.; Wyszynski, D. F.; Farrell, J. J.; Kutlar, A.; Farrer, L. A.; Baldwin, C. T.; Steinberg, M. H. // Pharmacogenomics Journal;2007, Vol. 7 Issue 6, p386 

    The increase in fetal hemoglobin (HbF) in response to hydroxyurea (HU) varies among patients with sickle cell anemia. Twenty-nine candidate genes within loci previously reported to be linked to HbF level (6q22.3–q23.2, 8q11–q12 and Xp22.2–p22.3), involved in metabolism of HU...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics